Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia
about
Update on rational targeted therapy in AMLAurora kinases as targets in drug-resistant neuroblastoma cellsA phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cellsAurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2.Dynamin inhibitors induce caspase-mediated apoptosis following cytokinesis failure in human cancer cells and this is blocked by Bcl-2 overexpression.Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells.Aurora kinase inhibitors as anticancer molecules.Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.Cell cycle control in acute myeloid leukemia.Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.Pharmacologic activation of p53 by small-molecule MDM2 antagonistsResults of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AMLHDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AMLAurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.Apoptosis in leukemias: regulation and therapeutic targeting.The p53 tumor suppressor protein regulates hematopoietic stem cell fate.ENMD-2076 for hematological malignancies.Molecular mechanisms controlling the cell cycle in embryonic stem cells.Targeting p53-MDM2-MDMX loop for cancer therapy.Bioactive compounds of Eriocaulon sieboldianum blocking proliferation and inducing apoptosis of HepG2 cells might be involved in Aurora kinase inhibition.CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express Aurora kinase A.Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53Axin1 expression facilitates cell death induced by aurora kinase inhibition through PARP activation.Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas.Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).EBNA3C-mediated regulation of aurora kinase B contributes to Epstein-Barr virus-induced B-cell proliferation through modulation of the activities of the retinoblastoma protein and apoptotic caspasesp53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.MDM2 Antagonists Counteract Drug-Induced DNA Damage.CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
P2860
Q26766152-8F10F32B-97D4-462D-872F-BA822B4D81F2Q28543446-F43C91C5-829B-41EC-A70F-2C122422B3F8Q33167422-4A4444A4-CFE5-4D69-BBAD-164FF5DC21CCQ33597514-1430147C-5CB8-42A4-B311-FE61B0B65F49Q33864179-DAF8ADA8-4F9C-45AB-9F23-2F9D52D3D6ABQ34095173-43D5E6FA-FB82-4546-9D49-BFB9CB5AEFDEQ35123993-D6581DC4-C0FF-4B61-B846-CA408B118216Q35696221-30BD89E1-8962-4129-9729-58040A81F4FDQ35850203-A3844376-A266-4E23-8E10-E01B665AF511Q36164893-50272F0B-20C9-4581-AF4F-87E47CBDF09DQ36206479-0B5C83F4-192C-4576-A3C3-1A2385226982Q36544358-BC49533F-5847-455C-9D2B-D7A940A8A0EEQ36731603-2E9BB080-6F2C-48FA-B8B6-D845B4250C5FQ36734163-D66DF716-B31B-4617-BDA7-3A1530211017Q37381120-21215BB4-3E65-494D-9691-E188B8706E8EQ37483191-29C87CEA-6624-4463-9D89-9F609457660AQ37690579-E43B5D9B-658E-4C49-92F1-80F43B14D9E7Q37715814-4525A1ED-EF76-487D-9ACA-02BAE9CBEC86Q37887629-E7BB9394-C68B-46CD-AE09-7F5672C8DFEEQ37991379-5601F0FE-D473-40EE-8455-8D692C29BA96Q38129768-931C9480-30D3-4C0B-B4CF-977EEB95ACD8Q38247168-1CF0221D-55B4-433C-A057-6E67A7848352Q38835387-88D35DC6-4DC7-4148-9CAC-D8227B98088DQ39149922-DED92135-4EC3-4A97-9821-DF9747C3425CQ39430447-F1F83C79-0D39-4164-BECA-13E99D911E1DQ39552816-50B67DE7-5CFC-4268-B541-0CFE7D024331Q39744147-F3860905-7DBB-40D8-A18B-7784275179BDQ39769534-C62D6583-B7B2-47C5-9735-B110883309E8Q40614153-C580BA50-7B74-4F71-AD65-EE8593FA1AB3Q42273501-F8906EA6-44A3-4BB8-9E8F-4BBB8F4D5C6EQ42362115-312342B1-CF20-4E67-A996-F3FFE685F9D1Q42651903-46061C26-AD0E-488F-9E06-14DC2CAC3780Q53075287-1B76D654-C7F0-44D0-9549-64FB3A80D1CBQ54498929-826F8387-7510-4271-A844-762A8BE509DE
P2860
Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Concomitant inhibition of Mdm2 ...... in acute myelogenous leukemia
@en
type
label
Concomitant inhibition of Mdm2 ...... in acute myelogenous leukemia
@en
prefLabel
Concomitant inhibition of Mdm2 ...... in acute myelogenous leukemia
@en
P2093
P2860
P1433
P1476
Concomitant inhibition of Mdm2 ...... in acute myelogenous leukemia
@en
P2093
Hideki Nakakuma
Kensuke Kojima
P2860
P304
P356
10.1182/BLOOD-2008-01-128611
P407
P577
2008-07-16T00:00:00Z